Pharmasset Presents Positive Results of Hepatitis Combination Study
Posted on: Monday, 28 April 2008, 09:00 CDT
Pharmasset has announced the promising results of a four-week Phase I clinical trial evaluating two oral dose levels of R7128 in combination with Pegasys plus Copegus in 50 treatment-naive patients chronically infected with hepatitis C virus genotype 1.
R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well tolerated. Approximately 85% of patients receiving R7128 1500mg twice-daily (BID) with Pegasys plus Copegus for four weeks achieved undetectable hepatitis C virus (HCV) RNA levels with safety and tolerability comparable to placebo with Pegasys plus Copegus.
John McHutchison, clinical investigator for this study, said: "R7128, in combination with Pegasys plus Copegus, has demonstrated Rapid Virologic Response (RVR) percentages in a four-week study that are similar to HCV protease inhibitors and has an encouraging short-term clinical safety profile. Longer-term studies of R7128 with Pegasys plus Copegus are needed to provide additional information about its potential to improve sustained virologic response rates for HCV patients."
Source: Datamonitor
Related Articles
- Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
- INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
- Telaprevir Presentations at the 59th AASLD Meeting to Feature SVR Data in Treatment-Naive and Treatment-Failure Genotype 1 HCV Patients, and Clinical Data Exploring Twice-Daily Dosing Regimens
- St. Jude Medical Announces First Patient Implants in Clinical Study Evaluating Deep Brain Stimulation for Depression
- Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study With CORTIJECT(R) for Diabetic Macular Edema
- MedImmune Begins Dosing of Lupus Patients in Phase 1 Clinical Trial
- New Study Demonstrates Clinical Efficacy of Telithromycin Superior to Standard First-Line Antibiotic Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia (CAP)
- GelStat Corporation Completes Patient Enrollment in Clinical Trial of GelStat Migraine in Triptan Users
 |
 |
User Comments (0)
RSS Feeds